Ardelyx (NASDAQ:ARDX) Insider Sells 15,136 Shares

Key Points

• Insider sale: Ardelyx insider James Parker Brady sold 15,136 shares at an average price of $3.86, generating $58,424.96. His remaining ownership fell 5.8% to 245,930 shares.
• Stock and earnings: ARDX rose 1.1% to $3.78, near its one-year low of $3.72. The company reported quarterly revenue of $120.88 million, up 34.3% year over year, but missed analysts’ EPS expectations with a loss of $0.07 per share.
• Analyst outlook: Ardelyx has a “Moderate Buy” consensus rating, with one Strong Buy, nine Buy and two Sell ratings. The consensus price target is $13.90, despite TD Cowen recently lowering its target to $10.

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider James Parker Brady sold 15,136 shares of Ardelyx stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $58,424.96. Following the transaction, the insider directly owned 245,930 shares of the company's stock, valued at approximately $949,289.80. This trade represents a 5.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ardelyx Stock Up 1.1%

NASDAQ:ARDX traded up $0.04 during mid-day trading on Tuesday, hitting $3.78. 3,418,138 shares of the company's stock were exchanged, compared to its average volume of 5,069,888. The company has a market cap of $941.94 million, a PE ratio of -17.18 and a beta of 0.70. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.34 and a quick ratio of 3.15. Ardelyx, Inc. has a one year low of $3.72 and a one year high of $8.40. The business has a fifty day moving average price of $4.97 and a 200 day moving average price of $5.75.

Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The business had revenue of $120.88 million for the quarter, compared to the consensus estimate of $121.03 million. During the same period in the prior year, the business posted ($0.08) EPS. Ardelyx's revenue for the quarter was up 34.3% on a year-over-year basis. Equities analysts predict that Ardelyx, Inc. will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Ardelyx

A number of institutional investors have recently made changes to their positions in ARDX. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Ardelyx during the second quarter valued at approximately $35,000. SCS Capital Management LLC purchased a new position in Ardelyx in the 2nd quarter worth approximately $52,000. ADAR1 Capital Management LLC bought a new position in Ardelyx in the 2nd quarter valued at approximately $56,000. State of Wyoming bought a new position in Ardelyx in the 2nd quarter valued at approximately $61,000. Finally, PVG Asset Management Corp bought a new position in Ardelyx in the 1st quarter valued at approximately $65,000. Hedge funds and other institutional investors own 58.92% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. TD Cowen reduced their price objective on Ardelyx from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, August 7th. LADENBURG THALM/SH SH initiated coverage on Ardelyx in a report on Tuesday, June 16th. They issued a "buy" rating and a $16.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Ardelyx in a research note on Friday, August 7th. Weiss Ratings cut Ardelyx from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, June 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $9.00 price target on shares of Ardelyx in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Ardelyx presently has an average rating of "Moderate Buy" and a consensus target price of $13.90.

Ardelyx Company Profile

Ardelyx, Inc NASDAQ: ARDX is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source